Play all audios:
A multidisciplinary expert panel from the American Society of Clinical Oncology has endorsed the updated European Association of Urology guidelines for the management of muscle-invasive
bladder cancer, with one exception. The panel also provides additional clarification of several recommendations. Access through your institution Buy or subscribe This is a preview of
subscription content, access via your institution RELEVANT ARTICLES Open Access articles citing this article. * THE PROGNOSTIC VALUE OF ROUTINE PREOPERATIVE BLOOD PARAMETERS IN
MUSCLE-INVASIVE BLADDER CANCER * Jingqi Zhang * , Xiaozhou Zhou * … Zhiwen Chen _BMC Urology_ Open Access 19 March 2020 * ASYMPTOMATIC RECURRENCE DETECTION AND COST-EFFECTIVENESS IN
UROTHELIAL CARCINOMA * Hiromichi Iwamura * , Shingo Hatakeyama * … Chikara Ohyama _Medical Oncology_ Open Access 09 May 2018 * A NOVEL BLADDER CANCER - SPECIFIC ONCOLYTIC ADENOVIRUS BY CD46
AND ITS EFFECT COMBINED WITH CISPLATIN AGAINST CANCER CELLS OF CAR NEGATIVE EXPRESSION * Wenjuan Cao * , Junqiang Tian * … Ronald Rodriguez _Virology Journal_ Open Access 08 August 2017
ACCESS OPTIONS Access through your institution Subscribe to this journal Receive 12 print issues and online access $209.00 per year only $17.42 per issue Learn more Buy this article *
Purchase on SpringerLink * Instant access to full article PDF Buy now Prices may be subject to local taxes which are calculated during checkout ADDITIONAL ACCESS OPTIONS: * Log in * Learn
about institutional subscriptions * Read our FAQs * Contact customer support REFERENCES * Milowsky, M. I. _ et al_. Guideline on muscle-invasive and metastatic bladder cancer (European
Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. _J. Clin. Oncol._ 34, 1945–1952 (2016). Article Google Scholar * Nayan, M.
_ et al_. The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: a time-series analysis. _Can. Urol. Assoc. J._ 10, 25–30 (2016). Article
Google Scholar * International collaboration of trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled
trial. _Lancet_ 354, 533–540 (1999). * Grossman, H. B. _ et al_. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. _N. Engl. J.
Med._ 349, 859–866 (2003). Article CAS Google Scholar * Bochner, B. H. _ et al_. Comparing open radical cystectomy and robot-assisted laparoscopic radical cystectomy: a randomized
clinical trial. _Eur. Urol._ 67, 1042–1050 (2015). Article Google Scholar * Smith, N. D. _ et al_. The RAZOR (randomized open versus robotic cystectomy) trial: study design and trial
update. _BJU Int._ 115, 198–205 (2015). Article Google Scholar * Gray, P. J. _ et al_. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States:
results from the National Cancer Data Base. _Eur. Urol._ 63, 823–829 (2013). Article Google Scholar * Choi, W. _ et al_. Identification of distinct basal and luminal subtypes of
muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. _Cancer Cell_ 25, 152–165 (2014). Article CAS Google Scholar * Van Allen, E. M. _ et al_. Somatic
_ERCC2_ mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. _Cancer Discov._ 4, 1140–1153 (2014). Article CAS Google Scholar * Chou, R. _ et al_.
_Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer_ (Agency for Healthcare Research and Quality (US), 2015). Google Scholar Download references AUTHOR INFORMATION AUTHORS AND
AFFILIATIONS * Seth P. Lerner is at the Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street, Houston, Texas 77030, USA., Seth P. Lerner Authors * Seth P. Lerner
View author publications You can also search for this author inPubMed Google Scholar CORRESPONDING AUTHOR Correspondence to Seth P. Lerner. ETHICS DECLARATIONS COMPETING INTERESTS S.L. has
worked with BioCancell, Vaxxion Therapeutics, UroGen Pharma, Telesta Therapeutics, Sitka Biopharma, Neucleixx, Taris Biomedical, Ferring Pharmaceuticals and the Bladder Cancer Journal. He
has received grants from ENDO Intenational, FKD Therapies, Viventia Bio, Roche, Genentech and Genome DX. RIGHTS AND PERMISSIONS Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE
Lerner, S. ASCO endorses EAU muscle-invasive bladder cancer guidelines. _Nat Rev Urol_ 13, 440–441 (2016). https://doi.org/10.1038/nrurol.2016.114 Download citation * Published: 05 July 2016
* Issue Date: August 2016 * DOI: https://doi.org/10.1038/nrurol.2016.114 SHARE THIS ARTICLE Anyone you share the following link with will be able to read this content: Get shareable link
Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt content-sharing initiative